Navigation Links
NicOx' Naproxcinod ABPM Data Presented at American Heart Association
Date:11/7/2007

SOPHIA ANTIPOLIS, France, Nov. 7 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced that clinical results of an exploratory pharmacodynamic study for naproxcinod using Ambulatory Blood Pressure Monitoring (ABPM) were presented yesterday at the American Heart Association Scientific Sessions 2007, in Orlando, Florida. Naproxcinod is the first compound in the COX-Inhibiting Nitric Oxide Donator class of anti-inflammatory agents and is in clinical development for the treatment of the signs and symptoms of osteoarthritis. This ABPM study was designed to provide complementary blood pressure data to the ongoing phase 3 program. The data presented at the AHA showed that the blood pressure measurements for naproxcinod over 24 hours were consistently below those observed for naproxen, a currently marketed non-steroidal anti-inflammatory agent (NSAID). NSAIDs are known to have the detrimental effect of raising patients' blood pressure. The top-line results of this trial (the 104 study) were announced last December (see press release of December 8, 2006).

The presentation included line graphs displaying the hourly mean blood pressure measurements over 24 hours following a two week treatment period, during which naproxcinod or naproxen were administered twice daily. These graphs showed that the hourly systolic blood pressure (SBP) and diastolic blood pressure (DBP) values for naproxcinod were consistently below those observed in the naproxen group (see NOTE 1). In addition, the data suggest that the blood pressure effect of naproxcinod lasts for 7 to 8 hours after each administration.

Considering the average of the ABPM measurements over 24 hours the results showed an almost 2 mmHg reduction in SBP and DBP for naproxcinod compared to naproxen, in terms of the mean change from baseline, after a 2 week active treatment period. This difference did not reach statistical significance for SBP (p=0.101), the primary endpoint of the study, but did ac
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... quarter of fiscal year 2015 results on Thursday, January 22, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... in the UK has completed review of the Clinical Trial ... Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment ... the Phase 3 pivotal trial early in the first quarter ...
... MOUNTAIN VIEW, Calif., Dec. 14, 2010 VIVUS, Inc. (Nasdaq: ... part of its continuing effort to secure regulatory approval for ... Food and Drug Administration (FDA) designed to address items in ... 2010.  The company also announced that the Endocrine and Metabolic ...
Cached Medicine Technology:MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA 2MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA 3VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 3
(Date:12/22/2014)... Christmas is days away, and last minute gifts ... solution that will please: the Sublime Gift Card . ... $25 up to $350," says Kathy Heshelow, founder of ... wide array of skin care products and Skin Brushes." , ... , Gift delivery past shipping deadlines, or those last ...
(Date:12/22/2014)... NAPW honors Cheryl ... the Year. She is recognized with this prestigious distinction ... networking organization of professional women in the country, spanning ... Professional Women is a vibrant networking community with over ... Kreider is passionate and committed to best practices that ...
(Date:12/22/2014)... December 22, 2014 The ... professional development programs this month. Faculty have been ... on nurse educators fast-tracked for administrative leadership roles ... Development Program for Simulation Educators, featuring a curriculum ... of nursing education. , Twenty nurse educators ...
(Date:12/22/2014)... 22, 2014 Parker & Sons, Inc. ... in Arizona home contracting services reports a record number ... quality services in 2014. As a company that has ... 1970s, Parker and Sons is a business that is ... works side-by-side with other top quality companies in Arizona ...
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, has ... and launched a bamboo flooring promotion with great discounts, ... 30, 2015. , According to the CEO of the ... available today; it has a highly distinctive grain with ... woven bamboo is made by a unique manufacturing process ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
... author,s two-year period of severe depressionBROOKLYN, N.Y., Feb. 27 ... Temple kept a journal, in which the basic underlying ... intolerable, and the result is this fascinating book of ... 100 poems, Temple shares his heartfelt feelings of extremely ...
... Annual Net Sales Driven by Demand for Branded Products- ... from 2007- Provides 2009 Adjusted EPS Guidance Range of ... Pharmaceuticals (Nasdaq: ENDP ) today reported double-digit ... per share for the fourth quarter and full year ...
... Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced ... on Monday, March 9, 2009, at 4:30 p.m. EDT to ... results, and provide an update on recent corporate developments. To ... The live Webcast and replay access of the teleconference will ...
... /PRNewswire-Asia/ -- GE Healthcare, a,leading provider of ... solutions targeted for hospitals and outpatient imaging ... clinical capabilities,the suite provides the robust Web-based ... Dynamic Imaging. , ...
... to the media regarding the PLoS Medicine article published online ... patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated ... 2001. , ... San Diego, California ...
... marketing spend Hallmark Cards today unveiled its plans for a major TV ... A Cure™, campaign. This will be the third year of the ... breast cancer charities by the end of its 2009 Mother,s Day Campaign. ... ...
Cached Medicine News:Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14Health News:GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia 2Health News:GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 2Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 5Health News:Hallmark Cards Increases Investment In Cards For a Cure™ with Major Advertising and PR Campaign for Mother's Day 2009 2Health News:Hallmark Cards Increases Investment In Cards For a Cure™ with Major Advertising and PR Campaign for Mother's Day 2009 3
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
... Optronics MicroFire - Monochrome: An ... microscope camera with Firewire connectivity. ... imaging beyond 900nm. The camera ... a C-mount adapter and is ...
... the most technologically advanced Micro-dermabrasion machine ... USA after extensive research, it offers ... with maximum control and total flexibility ... to traditional methods because the complex ...
The Urine Legionella Antigen ELISA kit detects the presence of Legionella pneumophila serogroup1 antigen in urine....
Medicine Products: